All News

mediterraneansandwich-498379__180.jpg

Dietary Improvement in Psoriatic Arthritis

Jack Cush, MD

The results of the DIETA trial showed that dietary changes may control psoriatic arthritis (PsA) disease activity, independent of weight loss.  

Read Article
TNR,PSA,journal,0412

Now Available: TNR - Psoriatic Arthritis Journal Club

Jack Cush, MD

A recording of this week’s Tuesday Night Rheumatology is now available. This outstanding webinar featured a robust discussion of the EXCEED study and Discover-2 trial, with Drs. Philip Mease, Peter Nash, Jack Cush and Rachel Tate.

Read Article
RheumNow Podcast square

Male vs. Female Responders (4.15.2022)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal Reports from the past week on RheumNow.com - including fellowship COVID-19 concerns, the limits of T2T in gout and the real odds of RA remission with your first biologic. 

Read Article
child.guttate.psoriasis

Kids With Psoriasis Maintained with Long Term IL-17A Inhibitor

MedPage Today

Pediatric patients with moderate-to-severe plaque psoriasis obtained significant improvement in disease status for as long as 2 years with the interleukin (IL)-17A inhibitor ixekizumab (Taltz), long-term follow-up from a randomized trial showed.

Read Article
dementia,brain

Is Alzheimer's Risk Lower With TNF Inhibitors?

MedPage Today

Tumor necrosis factor (TNF) inhibitors for rheumatoid arthritis were linked with a lower risk of Alzheimer's disease and related dementia, but only in people with cardiovascular disease, data from the DREAM (Drug Repurposing for Effective Alzheimer's Medicines) study showed.

Read Article
QD Clinic - PsA Lessons from the Clinic What are the Safe Treatment Options for psoriatics who have HIV? QD Clinic is sponsored by RheumNow's PsA All the Way Campaign in April 2022 https://t.co/fh00ydSYd3 https://t.co/fpDl2tF4cw

Links:

Dr. John Cush RheumNow ( View Tweet)
Can IL-22 differentiate between IL-17 & TNF inhibitor #PSA responders? Pilot study 2 cohorts 81 PSA pts showed both biologics worked but somewhat better response in IL-17i Pts w/ low IL- & TNFi responses w/ high IL-22 levels. https://t.co/txyNl2OwTP

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: Males respond better than females? Ixekizumab trials in #PSA - 676 pts in Two Phase 3 RCTs - females had lower response rates than males in all measures (ACR20/50/70; MDA; DAPSA) F had ⬆️HAQ, enthesitis, but ⬇️CRP https://t.co/sjVJZ8uQA3 https://t.co/l7B2ICZWaJ

Links:

Dr. John Cush RheumNow ( View Tweet)
Register for Tuesday Night Rheumatology today! Join us as we discuss the controversies in PsA when it comes to diagnosis, treatment strategies, therapeutics and more. https://t.co/YXAmzvPfeK https://t.co/jtSd0Ig5IT

Links:

Dr. John Cush RheumNow ( View Tweet)
Large metanalysis looks at Quality of Life outcomes w/ Therapies in #PSA 37 RCTs = 14.115 PsA pts ◾️ bDMARDs > PBO ◾️ bDMARDs = MTX (or Tofa) ◾️ bDMARDs + MTX > MTX https://t.co/6DDsVjcdcr https://t.co/ljb6AOH3UK

Links:

Dr. John Cush RheumNow ( View Tweet)
QD Clinic - PsA Lessons from the Clinic LFT Elevations may be considered differently in PsA patients QD Clinic is sponsored by RheumNow's PsA All the Way Campaign in April 2022 https://t.co/dCaWx5OTda https://t.co/bRTVqQ4ZJj

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr. Laura Coates discusses Precision Medicine in PsA. https://t.co/ttKHZDGjyC https://t.co/XwahihZyGH

Links:

Dr. John Cush RheumNow ( View Tweet)
QD Clinic - PsA Lessons from the Clinic Reasons why PsA patient can lose biologic efficacy and what to do about it QD Clinic is sponsored by RheumNow's PsA All the Way Campaign in April 2022 https://t.co/Bxy1G68rU9 https://t.co/CLe9SHfRQJ

Links:

Dr. John Cush RheumNow ( View Tweet)
Combined Clinics for PsA Rheums and derms have long worked together in the management of our patients, but the idea of directly collaborating in a single clinic space was novel at the time. Over the years, it has become my favorite clinic of the week. https://t.co/uY1mZtlvaV https://t.co/5AZ2z2kSVG

Links:

Dr. John Cush RheumNow ( View Tweet)
Comparison of Tofa, ADA, PBO in OPAL #PSA studies - median time to HAQ response better for Tofa & ADA (30d) vs PBO (>112d), but Tofa had faster Fatigue response (31 vs 90+D). MDA response time same between Tofa v ADA #PSAlways https://t.co/f48Of7bEjN https://t.co/KvfQUbLwCH

Links:

Dr. John Cush RheumNow ( View Tweet)
NPF COVID-19 report from AAD mtg shows #PSA pts on systemic Rx were not at risk of hospitalization or severe COVID-1 based on US claims data. Also TNFi, IL-17, IL-23 Rx not affect on Vax Ab responses; less hosp (36%) w/ TNFi https://t.co/ekvu0mMvrn https://t.co/Qogm1Vx5hF

Links:

Dr. John Cush RheumNow ( View Tweet)
Ixekizumab in 1401 #PSA pts w/ 2248 Pt-Yrs exposure showed Serious AE in 134 pts. Most common AEs were nasopharyngitis & URI. Incidence of SAE (≤1.2/100PY), cancer (0.7/100PY), IBD (0.1/00PY), depression (1.6/100PY) were low. #PSAlways https://t.co/YGGj4XCQDM

Links:

Dr. John Cush RheumNow ( View Tweet)

ArthritisPower study of 332 #PsA pts finds patients are most bothered by joint pain, MSK pain & fatigue. Patients prefer oral, QD meds; 3/4 want Rx that improved joints vs skin; and would prefer to avoid MTX https://t.co/WYqWgoimOT https://t.co/RgGeCKrpT1

Links:

Dr. John Cush RheumNow ( View Tweet)
2020 Pt preferences survey- 137 #PsA pts most took TNFi (30%), IL-17i (20%), MTX (10%). From 2018 to 2020 a signif incr in IL-17i & PDE4 inhib. Pts want Rx for damage (80%), ADL (71%), & pain (70%) https://t.co/2dyIuQubh5 https://t.co/sFbtRj0Lbv

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Deucravacitinib, TYK2 inhib, studied in phase II trial 203 active PsA pts randomised to PBO, or DEUC 6 mg or 12 mg qd. At wk 16 ACR-20 responses were significantly higher with DEUC 6mg (53%, p=0.0134) and 12 mg (63%, p=0.0004) vs PBO. https://t.co/UOPteZY0g8 https://t.co/Xw3ZSPWeE0

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×